.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Mallinckrodt
Farmers Insurance
US Army
Novartis
UBS
Dow
Harvard Business School
Cantor Fitzgerald

Generated: June 24, 2017

DrugPatentWatch Database Preview

Pitavastatin calcium - Generic Drug Details

« Back to Dashboard

What are the generic sources for pitavastatin calcium and what is the scope of pitavastatin calcium freedom to operate?

Pitavastatin calcium
is the generic ingredient in two branded drugs marketed by Aurobindo Pharma Ltd, Orient Pharma Co Ltd, Sawai Usa, and Kowa Co, and is included in four NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Pitavastatin calcium has fifty-five patent family members in nineteen countries.

There are thirteen drug master file entries for pitavastatin calcium. Two suppliers are listed for this compound.

Summary for Generic Name: pitavastatin calcium

Tradenames:2
Patents:5
Applicants:4
NDAs:4
Drug Master File Entries: see list13
Suppliers / Packagers: see list2
Bulk Api Vendors: see list72
Clinical Trials: see list1,806
Patent Applications: see list6,014
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:pitavastatin calcium at DailyMed

Pharmacology for Ingredient: pitavastatin calcium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sawai Usa
PITAVASTATIN CALCIUM
pitavastatin calcium
TABLET;ORAL205955-001Feb 3, 2017ABRXNoNo► Subscribe► Subscribe
Kowa Co
LIVALO
pitavastatin calcium
TABLET;ORAL022363-001Aug 3, 2009ABRXYesNo6,465,477► SubscribeY ► Subscribe
Kowa Co
LIVALO
pitavastatin calcium
TABLET;ORAL022363-003Aug 3, 2009ABRXYesYes6,465,477► SubscribeY ► Subscribe
Kowa Co
LIVALO
pitavastatin calcium
TABLET;ORAL022363-002Aug 3, 2009ABRXYesNo7,022,713► Subscribe ► Subscribe
Kowa Co
LIVALO
pitavastatin calcium
TABLET;ORAL022363-001Aug 3, 2009ABRXYesNo5,856,336► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: pitavastatin calcium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Kowa Co
LIVALO
pitavastatin calcium
TABLET;ORAL022363-002Aug 3, 20096,465,477► Subscribe
Kowa Co
LIVALO
pitavastatin calcium
TABLET;ORAL022363-001Aug 3, 20095,753,675► Subscribe
Kowa Co
LIVALO
pitavastatin calcium
TABLET;ORAL022363-001Aug 3, 20096,465,477► Subscribe
Kowa Co
LIVALO
pitavastatin calcium
TABLET;ORAL022363-002Aug 3, 20095,753,675► Subscribe
Kowa Co
LIVALO
pitavastatin calcium
TABLET;ORAL022363-002Aug 3, 20095,854,259► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: pitavastatin calcium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,102,888 Quinoline type mevalonolactones useful for treating hyperlipidemia and related diseases► Subscribe
5,854,259 Quinoline type mevalonolactones► Subscribe
5,872,130 Quinoline type mevalonoactones► Subscribe
8,853,405Crystalline forms of pitavastatin calcium► Subscribe
5,185,328 Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: pitavastatin calcium

Country Document Number Estimated Expiration
JapanH01279866► Subscribe
Cyprus1110133► Subscribe
Spain2342609► Subscribe
Japan5474276► Subscribe
South Korea960000852► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Fish and Richardson
Medtronic
Citi
UBS
Merck
Baxter
Mallinckrodt
Farmers Insurance
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot